Trained donor cells take aim at Hard-to-Treat blood cancers

This early-phase study tests a new therapy using specially trained immune cells from a donor to target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose disease has returned or not gone away after a stem cell transplant. The cells are grown in a lab to recognize four proteins common on these cancer cells. The main goal is to find the safest dose and see if the cells can shrink or control the cancer.